在B细胞枯竭治疗期间,自抗体的Fab糖化水平升高维持在B细胞枯竭治疗期间
Anika M Valk1,2,3, Jana Koers1,3, Ninotska I L Derksen1
1Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center, Plesmanlaan 125, 1066 CX, Amsterdam, The Netherlands.
Scientific reports
|April 28, 2025
概括
乙细胞枯竭疗法对风湿性关节炎和黄虫等自身免疫性疾病的IgG总糖化产生影响,但自身抗体Fab糖化保持稳定,这表明其具有生物标志物潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 葡萄糖生物学 葡萄糖生物学
- 自免疫性疾病 自免疫性疾病
背景情况:
- 在慢性自身免疫性疾病中观察到高的Fab抗体糖化.
- 糖在疾病状态和发展中的作用尚不清楚,但可能作为生物标志物.
- B细胞枯竭疗法减少了自身抗体,这引发了关于它们对Fab糖化酶的作用的问题.
研究的目的:
- 研究B细胞枯竭疗法对Fab总IgG和IgG自身抗体的糖化对B细胞枯竭疗法的纵向影响.
- 在类风湿性关节炎 (RA),黄 (PV),ANCA相关血管炎 (AAV) 和多发性硬化症 (MS) 中评估Fab糖化变化.
主要方法:
- 纵向研究比较基线Fab糖化与治疗后6-12个月.
- 莱克亲和色谱用于确定Fab化作为Fab糖化化的估计.
- 在RA,PV,AAV和MS患者中分析总IgG和IgG自身抗体.
主要成果:
- 在RA和PV患者中观察到总IgG Fab糖化酶的适度下降.
- 在AAV患者中,总IgG的Fab糖化略有增加;在MS患者中没有发现任何变化.
- 自体抗体标位下降,但尽管接受了B细胞耗尽疗法,它们的Fab糖化水平仍然很高.
结论:
- 自体抗体的Fab糖化水平在B细胞枯竭治疗时不会下降.
- 自体抗体Fab糖基化保留了其预测潜力,作为这些自身免疫性疾病中的生物标志物.
相关概念视频
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:24B Cell Activation and Differentiation
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...